

## **Amendment of Consolidated Financial Results for 9 Months Ended 31 Dec. 2005**

Tokyo, Japan – 2 February 2006: Sosei Co. Ltd. (“Sosei” – 4565, Tokyo Stock Exchange MOTHERS index) notifies following amendment of “Summary of Consolidated Financial Results for the Nine Months Ended 31st December 2005 (FY2005/2006)” which was released on 31<sup>st</sup> of January 2006:

(Amendment as underlined)

Summary of Consolidated Financial Results for the Nine Months Ended 31st December 2005 (FY2005/2006)

4. Quarterly Consolidated Financial Statements

(3) Consolidated Surplus Statement (Page 6)

Apr. 1, 2005 – Dec. 31, 2005

Released:	Capital increase through new stock issue	9,310,119
	Capital surplus, end of period	17,234,094
Amended:	Capital increase through new stock issue	<u>9,313,119</u>
	Capital surplus, end of period	<u>17,237,094</u>

- end -

### **Enquiries**

**Sosei Co. Ltd.**

**Tel: +81 (0)3 5210 3399**

Yoshiyuki YAMAKAWA, Representative Executive Officer & CFO or Hiroki MAEKAWA, Director of Corporate Planning

### **Notes to Editors:**

#### **About Sosei**

Sosei Co. Ltd. is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

In August 2005, Sosei expanded its international presence through the acquisition of the UK-based private biopharmaceutical company Arakis Limited.

For further information about Sosei, please visit [www.sosei.com](http://www.sosei.com).